Key facts
- This page summarizes David R. McAvoy's Form 4 filing for Fresh Tracks Therapeutics, Inc..
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 Oct 2023, 21:40.
David R. McAvoy - 02 Oct 2023 Form 4 Insider Report for Fresh Tracks Therapeutics, Inc.
- Reporting relationship
- Gen Counsel, CCO, & Secretary
- Issuer ticker
- N/A
- Reported as of
- 02 Oct 2023
- Net transaction value
- -$7,209
- SEC form
- 4
- Accepted by SEC
- 04 Oct 2023, 21:40:24 UTC
- Prior SEC filing
- 26 Jan 2023
- Next SEC filing
- 05 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christine G. Long, Attorney-in-Fact for David R. McAvoy (power of attorney previously filed)
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David R. McAvoy filed Form 4 for Fresh Tracks Therapeutics, Inc. on 04 Oct 2023.
Change
- Previous filing in this sequence was filed on 26 Jan 2023.
- Current net transaction value: -$7,209.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
FRTX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +20,000
- Change %
- +585%
- Price
- Shares after
- 23,419
- Date
- 02 Oct 2023
- Ownership
- Direct
- Footnotes
- F1, F2, F3, F4
FRTX
transaction
Common Stock
Tax liability
- Transaction value
- $7,209
- Shares
- -7,358
- Change %
- -31%
- Price
- $0.9798
- Shares after
- 16,061
- Date
- 02 Oct 2023
- Ownership
- Direct
- Footnotes
- F5
FRTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 310
- Date
- 02 Oct 2023
- Ownership
- By spouse
- Footnotes
- F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
FRTX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -20,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 02 Oct 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,000
- Exercise price
- Footnotes
- F2, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
David R. McAvoy is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 6 footnotes
Footnote F1
The restricted stock units were granted on January 24, 2023 and were subject to accelerated vesting as of the date of the reporting person's termination pursuant to his employment agreement with the issuer.
Footnote F2
Each restricted stock unit converted into common stock on a one-for-one basis.
Footnote F3
This balance includes 555 shares purchased under the Fresh Tracks Therapeutics, Inc. Employee Stock Purchase Plan that were not previously reported.
Footnote F4
On July 5, 2022, the registrant effected a 1-for-45 reverse stock split ("Reverse Stock Split") of its common stock. The number of shares beneficially owned has been adjusted to give effect to the Reverse Stock Split.
Footnote F5
Represents shares withheld by the issuer to satisfy tax withholding obligations upon the vesting of restricted stock units.
Footnote F6
The restricted stock units vested in full on October 2, 2023.